Compare · AMS vs ILMN
AMS vs ILMN
Side-by-side comparison of American Shared Hospital Services (AMS) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMS and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $41.04B, about 4858.9x AMS ($8.4M).
- ILMN has hit the wire 8 times in the past 4 weeks while AMS has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for AMS).
- Company
- American Shared Hospital Services
- Illumina Inc.
- Price
- $1.48+2.43%
- $262.52-2.06%
- Market cap
- $8.4M
- $41.04B
- 1M return
- +2.43%
- -
- 1Y return
- -35.87%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- AMEX
- NASDAQ
- IPO
- 1988
- 2000
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
American Shared Hospital Services
American Shared Hospital Services leases radiosurgery and radiation therapy equipment to health care providers. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. As of March 1, 2021, it had thirteen operating Gamma Knife units located in the United States, as well as two in South America in Lima, Peru and Guayaquil, Ecuador. The company also operates one PBRT system. American Shared Hospital Services was founded in 1980 and is headquartered in San Francisco, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest AMS
- SEC Form 10-Q filed by American Shared Hospital Services
- American Shared Hospital Services filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- American Shared Hospital Services Reports Second Quarter and First Half 2026 Financial Results
- American Shared Hospital Services Announces Second Quarter 2026 Financial Results Conference Call
- American Shared Hospital Services filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 4 filed by Executive Chairman Stachowiak Raymond C
- New insider Tirrito Alexis claimed ownership of 9,634 units of Common Stock No Par Value (SEC Form 3)
- American Shared Hospital Services filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- American Shared Hospital Services filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Executive Chairman Stachowiak Raymond C bought $1,337,147 worth of Common Stock No Par Value (586,468 units at $2.28) (SEC Form 4)
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)